背景疲乏是慢性肾脏病(CKD)患者最常见的症状,并且与较低的生活质量和较高的死亡风险密切相关。目前常用患者报告结局评估量表(PROM)评估CKD相关疲乏,然而此类量表形式各异,适用人群有所侧重,尚未形成一致的共识,影响临床选择应用。目...背景疲乏是慢性肾脏病(CKD)患者最常见的症状,并且与较低的生活质量和较高的死亡风险密切相关。目前常用患者报告结局评估量表(PROM)评估CKD相关疲乏,然而此类量表形式各异,适用人群有所侧重,尚未形成一致的共识,影响临床选择应用。目的系统评价各量表的优缺点及适用人群,为临床工作者选择合适的评估量表提供参考。方法系统检索PubMed、Web of Science、中国知网、维普网、万方数据知识服务平台,筛选与CKD疲乏评估相关文献,检索时间限制为2018年1月—2024年4月,数据由两位研究者独立筛选和提取,通过对比各量表的评估方式、优缺点等,探索分析不同CKD人群疲乏评估量表的选择。结果CKD相关疲乏量表主要分为普适性量表和特殊人群量表,量表均采用Likert法评估。健康状况调查量表、透析症状指数量表(DSI)适用于CKD疲乏症状的筛查;Piper疲乏修订量表(PFS-R)作为多维度量表,临床应用最广泛,能够明确区分疲乏程度和维度,可能较适合CKD患者的疲乏评估。结论CKD相关疲乏评估量表众多,临床从业者需综合考虑CKD研究人群特点,选择疲乏评估量表。展开更多
BACKGROUND Helicobacter pylori(H.pylori)infection is highly prevalent worldwide,and rising antibiotic resistance has reduced the efficacy of standard therapy,underscoring the need for simplified and better-tolerated r...BACKGROUND Helicobacter pylori(H.pylori)infection is highly prevalent worldwide,and rising antibiotic resistance has reduced the efficacy of standard therapy,underscoring the need for simplified and better-tolerated regimens.AIM To evaluate the efficacy,safety,and optimal dosing of vonoprazan(VPZ)-amoxicillin(AMO)dual therapy in a non-inferiority randomized trial for H.pylori eradication.METHODS In this multi-center,randomized trial conducted at 17 hospitals in Sichuan Province,China,1717 adults with confirmed infection were assigned(1:1:1)to 14-day regimens:(1)VPZ 20 mg BID+AMO 0.5 g QID;(2)0.75 g QID;or(3)1.0 g TID.The primary endpoint was the eradication rate based on intention-to-treat(ITT)and per-protocol(PP)analyses;secondary endpoints included adverse events(AEs)and treatment compliance.RESULTS Eradication rates were consistently high(92.35%-97.43%).In the 0.5 g QID group,ITT and PP eradication rates were 93.3%(95%CI:91.2-95.1)and 97.4%(95%CI:95.7-98.5),respectively,with no significant differences among groups(P>0.05).Compliance ranged from 98.1%to 98.3%,and AEs were infrequent(5.2%-7.5%),predominantly mild gastrointestinal symptoms,which occurred least often in the 0.5 g QID group.CONCLUSION VPZ-AMO dual therapy achieved excellent eradication,safety,and patient compliance.All regimens were similarly effective,whereas the 0.5 g QID dosing strategy offered the most favorable balance of efficacy and tolerability,supporting its use as a first-line option in high-prevalence settings.展开更多
To construct and express the fusion protein Stx2B-IntiminC300 of EHEC O157 ： H7, and to further investigate its immunoprophylactic potential, the gene of Stx2B （stx2b） from EHEC O157：H7 chromosome was cloned into ...To construct and express the fusion protein Stx2B-IntiminC300 of EHEC O157 ： H7, and to further investigate its immunoprophylactic potential, the gene of Stx2B （stx2b） from EHEC O157：H7 chromosome was cloned into pMD18-T vector. Thereafter, the amplified gene was cloned into prokary- otic expression plasmid pET-28a （ ＋ ）-eaeC300, which was constructed previously. The recombinant pasmid pET-28a（ ＋ ）-stx2b-eaeC300 was transformed into E. coli BL21 （DE3）. After inducement, the protein Stx2B-IntiminC300 was successfully expressed and analyzed with sodium dodecyl sulfate polyacrylamide gel electrophoresis （SDS-PAGE）, Western blotting and N-terminal amino acid residual sequencing. To evaluate its immunoprophylactic potential, it was primarily purified by ion-exchange chromatography and injected into 30 BALB/c mice with AI（OH）3 in the subscapular region. Ten days after the last booster vaccination, 20 mice were attacked with EHEC O157：H7 lysate and the protective efficacy was observed. In the present study, the gene of Stx2B-intiminC300 was successfully cloned into pET-28a （ ＋ ） vector. The results of SDS-PAGE and Western blotting assay showed that the fusion protein was successfully expressed in the inclusion body form, accounting for 25 % of total expression products, and its molecular weight was about 43 kDa. The result of the N-terminal amino acid residual sequencing showed that it was identical to that of the molecular designed. The purity was about 75 % after primary purification. Animal tests revealed that the fusion protein Stx2B-intiminC300 has elicited high titer of protective antibody relatively. These results demonstrate that the fusion protein Stx2B-IntiminC300 is successfully expressed in prokaryotic expression system and shows certain immunoprophylactic potential.展开更多
文摘背景疲乏是慢性肾脏病(CKD)患者最常见的症状,并且与较低的生活质量和较高的死亡风险密切相关。目前常用患者报告结局评估量表(PROM)评估CKD相关疲乏,然而此类量表形式各异,适用人群有所侧重,尚未形成一致的共识,影响临床选择应用。目的系统评价各量表的优缺点及适用人群,为临床工作者选择合适的评估量表提供参考。方法系统检索PubMed、Web of Science、中国知网、维普网、万方数据知识服务平台,筛选与CKD疲乏评估相关文献,检索时间限制为2018年1月—2024年4月,数据由两位研究者独立筛选和提取,通过对比各量表的评估方式、优缺点等,探索分析不同CKD人群疲乏评估量表的选择。结果CKD相关疲乏量表主要分为普适性量表和特殊人群量表,量表均采用Likert法评估。健康状况调查量表、透析症状指数量表(DSI)适用于CKD疲乏症状的筛查;Piper疲乏修订量表(PFS-R)作为多维度量表,临床应用最广泛,能够明确区分疲乏程度和维度,可能较适合CKD患者的疲乏评估。结论CKD相关疲乏评估量表众多,临床从业者需综合考虑CKD研究人群特点,选择疲乏评估量表。
基金Supported by Project Fund of the Health Commission of Sichuan Province,No.19PJ290。
文摘BACKGROUND Helicobacter pylori(H.pylori)infection is highly prevalent worldwide,and rising antibiotic resistance has reduced the efficacy of standard therapy,underscoring the need for simplified and better-tolerated regimens.AIM To evaluate the efficacy,safety,and optimal dosing of vonoprazan(VPZ)-amoxicillin(AMO)dual therapy in a non-inferiority randomized trial for H.pylori eradication.METHODS In this multi-center,randomized trial conducted at 17 hospitals in Sichuan Province,China,1717 adults with confirmed infection were assigned(1:1:1)to 14-day regimens:(1)VPZ 20 mg BID+AMO 0.5 g QID;(2)0.75 g QID;or(3)1.0 g TID.The primary endpoint was the eradication rate based on intention-to-treat(ITT)and per-protocol(PP)analyses;secondary endpoints included adverse events(AEs)and treatment compliance.RESULTS Eradication rates were consistently high(92.35%-97.43%).In the 0.5 g QID group,ITT and PP eradication rates were 93.3%(95%CI:91.2-95.1)and 97.4%(95%CI:95.7-98.5),respectively,with no significant differences among groups(P>0.05).Compliance ranged from 98.1%to 98.3%,and AEs were infrequent(5.2%-7.5%),predominantly mild gastrointestinal symptoms,which occurred least often in the 0.5 g QID group.CONCLUSION VPZ-AMO dual therapy achieved excellent eradication,safety,and patient compliance.All regimens were similarly effective,whereas the 0.5 g QID dosing strategy offered the most favorable balance of efficacy and tolerability,supporting its use as a first-line option in high-prevalence settings.
文摘To construct and express the fusion protein Stx2B-IntiminC300 of EHEC O157 ： H7, and to further investigate its immunoprophylactic potential, the gene of Stx2B （stx2b） from EHEC O157：H7 chromosome was cloned into pMD18-T vector. Thereafter, the amplified gene was cloned into prokary- otic expression plasmid pET-28a （ ＋ ）-eaeC300, which was constructed previously. The recombinant pasmid pET-28a（ ＋ ）-stx2b-eaeC300 was transformed into E. coli BL21 （DE3）. After inducement, the protein Stx2B-IntiminC300 was successfully expressed and analyzed with sodium dodecyl sulfate polyacrylamide gel electrophoresis （SDS-PAGE）, Western blotting and N-terminal amino acid residual sequencing. To evaluate its immunoprophylactic potential, it was primarily purified by ion-exchange chromatography and injected into 30 BALB/c mice with AI（OH）3 in the subscapular region. Ten days after the last booster vaccination, 20 mice were attacked with EHEC O157：H7 lysate and the protective efficacy was observed. In the present study, the gene of Stx2B-intiminC300 was successfully cloned into pET-28a （ ＋ ） vector. The results of SDS-PAGE and Western blotting assay showed that the fusion protein was successfully expressed in the inclusion body form, accounting for 25 % of total expression products, and its molecular weight was about 43 kDa. The result of the N-terminal amino acid residual sequencing showed that it was identical to that of the molecular designed. The purity was about 75 % after primary purification. Animal tests revealed that the fusion protein Stx2B-intiminC300 has elicited high titer of protective antibody relatively. These results demonstrate that the fusion protein Stx2B-IntiminC300 is successfully expressed in prokaryotic expression system and shows certain immunoprophylactic potential.
